{"id":164925,"date":"2023-01-18T00:35:42","date_gmt":"2023-01-18T05:35:42","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/"},"modified":"2024-08-18T11:46:53","modified_gmt":"2024-08-18T15:46:53","slug":"junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china.php","title":{"rendered":"Junshi Biosciences Announces Acceptance of NDA for VV116 in China"},"content":{"rendered":"<p><![CDATA[SHANGHAI, China, Jan.  17, 2023  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the new drug application (\u201cNDA\u201d) for Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 drug, has been accepted by the National Medical Products Administration (the \u201cNMPA\u201d) for the treatment of the coronavirus disease 2019 (\u201cCOVID-19\u201d).]]><\/p>\n<p>Read more:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/01\/18\/2590588\/0\/en\/Junshi-Biosciences-Announces-Acceptance-of-NDA-for-VV116-in-China.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Junshi Biosciences Announces Acceptance of NDA for VV116 in China\">Junshi Biosciences Announces Acceptance of NDA for VV116 in China<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more: Junshi Biosciences Announces Acceptance of NDA for VV116 in China <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-164925","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164925"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=164925"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164925\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=164925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=164925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=164925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}